Suspected clonal hematopoiesis as a natural functional assay of TP53 germline variant pathogenicity

Genet Med. 2022 Mar;24(3):673-680. doi: 10.1016/j.gim.2021.10.018. Epub 2021 Nov 30.

Abstract

Purpose: Some variants identified by multigene panel testing of DNA from blood present with low variant allele fraction (VAF), often a manifestation of clonal hematopoiesis. Research has shown that the proportion of variants with low VAF is especially high in TP53, the Li-Fraumeni syndrome gene. Based on the hypothesis that variants with low VAF are positively selected as drivers of clonal hematopoiesis, we investigated the use of VAF as a predictor of TP53 germline variant pathogenicity.

Methods: We used data from 260,681 TP53 variants identified at 2 laboratories to compare the distribution of pathogenic and benign variants at different VAF intervals.

Results: Likelihood ratios toward pathogenicity associated with a VAF < 26% equated to the American College of Medical Genetics/Association of Molecular Pathology strong strength level and were applicable for 1 in 5 variants of unknown significance.

Conclusion: In conclusion, detection of variants with low VAF in blood can be considered an in vivo functional assay to aid assessment of TP53 variant pathogenicity.

Keywords: ACMG; Clonal hematopoiesis; Li-Fraumeni syndrome; TP53; Variant allele fraction; Variant classification.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clonal Hematopoiesis*
  • Genetic Predisposition to Disease*
  • Germ-Line Mutation / genetics
  • Humans
  • Tumor Suppressor Protein p53 / genetics

Substances

  • TP53 protein, human
  • Tumor Suppressor Protein p53